| Segment / region | Type | Fiscal year | Currency | Revenue (millions) | Share of revenue |
|---|---|---|---|---|---|
| UNITED STATES | Region | 2025 | USD | 3,543.1 | 58.4% |
| Europe | Region | 2025 | USD | 1,517.5 | 25.0% |
| Rest of World | Region | 2025 | USD | 652.3 | 10.8% |
| JAPAN | Region | 2025 | USD | 354.7 | 5.9% |
| UNITED STATES | Region | 2024 | USD | 3,206.0 | 58.9% |
| Europe | Region | 2024 | USD | 1,321.7 | 24.3% |
| Rest of World | Region | 2024 | USD | 572.0 | 10.5% |
| JAPAN | Region | 2024 | USD | 339.8 | 6.3% |
| UNITED STATES | Region | 2023 | USD | 3,508.7 | 58.4% |
| Europe | Region | 2023 | USD | 1,334.5 | 22.2% |
| Rest of World | Region | 2023 | USD | 709.2 | 11.8% |
| JAPAN | Region | 2023 | USD | 452.4 | 7.5% |
| UNITED STATES | Region | 2022 | USD | 3,132.6 | 58.2% |
| Europe | Region | 2022 | USD | 1,174.8 | 21.8% |
| Rest of World | Region | 2022 | USD | 601.4 | 11.2% |
| JAPAN | Region | 2022 | USD | 473.6 | 8.8% |
| UNITED STATES | Region | 2021 | USD | 2,963.1 | 56.6% |
| Europe | Region | 2021 | USD | 1,190.3 | 22.8% |
| Rest of World | Region | 2021 | USD | 550.2 | 10.5% |
| JAPAN | Region | 2021 | USD | 528.9 | 10.1% |
| UNITED STATES | Region | 2020 | USD | 2,516.8 | 57.4% |
| Europe | Region | 2020 | USD | 973.6 | 22.2% |
| JAPAN | Region | 2020 | USD | 460.1 | 10.5% |
| Rest of World | Region | 2020 | USD | 435.8 | 9.9% |
| Transcatheter Heart Valves | Product | 2025 | USD | 4,487.7 | 74.0% |
| Surgical Heart Valve Therapy | Product | 2025 | USD | 1,029.3 | 17.0% |
| Transcatheter Mitral And Tricuspid Therapies | Product | 2025 | USD | 550.6 | 9.1% |
| Transcatheter Heart Valves | Product | 2024 | USD | 4,106.1 | 75.5% |
| Surgical Heart Valve Therapy | Product | 2024 | USD | 981.3 | 18.0% |
| Transcatheter Mitral And Tricuspid Therapies | Product | 2024 | USD | 352.1 | 6.5% |
| Transcatheter Heart Valves | Product | 2023 | USD | 3,879.8 | 64.6% |
| Surgical Heart Valve Therapy | Product | 2023 | USD | 999.3 | 16.6% |
| Critical Care | Product | 2023 | USD | 928.1 | 15.5% |
| Transcatheter Mitral And Tricuspid Therapies | Product | 2023 | USD | 197.6 | 3.3% |
| Transcatheter Heart Valves | Product | 2022 | USD | 3,518.2 | 65.4% |
| Surgical Heart Valve Therapy | Product | 2022 | USD | 893.1 | 16.6% |
| Critical Care | Product | 2022 | USD | 855.0 | 15.9% |
| Transcatheter Mitral And Tricuspid Therapies | Product | 2022 | USD | 116.1 | 2.2% |
| Transcatheter Heart Valves | Product | 2021 | USD | 3,422.5 | 65.4% |
| Surgical Heart Valve Therapy | Product | 2021 | USD | 889.1 | 17.0% |
| Critical Care | Product | 2021 | USD | 834.9 | 16.0% |
| Transcatheter Mitral And Tricuspid Therapies | Product | 2021 | USD | 86.0 | 1.6% |
| Transcatheter Heart Valves | Product | 2020 | USD | 2,857.3 | 65.1% |
| Surgical Heart Valve Therapy | Product | 2020 | USD | 761.8 | 17.4% |
| Critical Care | Product | 2020 | USD | 725.4 | 16.5% |
| Transcatheter Mitral And Tricuspid Therapies | Product | 2020 | USD | 41.8 | 1.0% |
Product and geographic breakdowns describe the same revenue from different perspectives and should not be added together.
